Avalyn Pharma restructures governance for IPO, creates dual-class stock with 200M non-voting shares

Filed May 1, 2026 · Period ending May 1, 2026 · ~1 min read

Key Changes

• high

  Company authorized 700M common shares split into 500M voting and 200M non-voting shares, creating a dual-class structure that may concentrate voting control with insiders or early investors.

  Item 5.03 verify on EDGAR →
• high

  Board granted authority to issue up to 10M shares of undesignated preferred stock in future series without shareholder approval, potentially diluting common stockholders.

  Item 5.03 verify on EDGAR →
• medium

  New bylaws require advance notice for stockholder proposals and director nominations, making it harder for retail investors to participate in governance without planning ahead.

  Item 5.03 verify on EDGAR →